IQVIA(US:IQV) ZACKSยท2024-11-01 01:31Core Insights - IQVIA Holdings reported revenue of $3.9 billion for the quarter ended September 2024, reflecting a 4.3% increase year-over-year and a surprise of +1.11% over the Zacks Consensus Estimate of $3.85 billion [1] - Earnings per share (EPS) for the quarter was $2.84, up from $2.49 in the same quarter last year, exceeding the consensus EPS estimate of $2.81 by +1.07% [1] Financial Performance Metrics - Backlog stood at $31.1 billion, slightly below the average estimate of $31.31 billion from two analysts [3] - Revenue from Technology & Analytics Solutions was $1.55 billion, surpassing the average estimate of $1.49 billion, marking an 8.6% year-over-year increase [3] - Revenue from Research & Development Solutions reached $2.16 billion, slightly below the average estimate of $2.19 billion, with a year-over-year change of +1.9% [3] - Revenue from Contract Sales & Medical Solutions was $180 million, exceeding the estimated $176.87 million, but showing a -1.6% change compared to the previous year [3] - Segment profit for Technology & Analytics Solutions was $405 million, above the average estimate of $364.08 million [3] - Segment profit for Contract Sales & Medical Solutions was $12 million, below the average estimate of $19.06 million [3] - Segment profit for Research & Development Solutions was $405 million, significantly lower than the average estimate of $517.57 million [3] Stock Performance - IQVIA shares have returned -6.8% over the past month, contrasting with the Zacks S&P 500 composite's +1% change [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [4]